Introduction Cosentyx is the brand name of secukinumab, a fully human monoclonal antibody used in immune-mediated inflammatory diseases. It belongs to the class of interleukin-17A inhibitors, also called IL-17A antagonists. Cosentyx is important in pharmacology because it targets a specific inflammatory cytokine rather than producing broad immunosuppression like corticosteroids. It is used in conditions where … Read more
Introduction Fasenra is the brand name of benralizumab, a humanized monoclonal antibody used mainly in the management of severe eosinophilic asthma. It belongs to the class of biologic anti-eosinophilic therapies and is especially important in patients whose asthma remains uncontrolled despite standard inhaled corticosteroid and long-acting bronchodilator therapy. Unlike conventional asthma medicines such as beta-2 … Read more
Introduction Natalizumab is a humanized IgG4 monoclonal antibody targeting the α4 integrin subunit. It’s approved for relapsing-remitting multiple sclerosis (RRMS) and moderate to severe Crohn’s disease. By blocking leukocyte adhesion, it prevents immune cell migration into the brain and gut. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Intravenous infusion Half-life ~11 days Distribution … Read more
Introduction Adalimumab is a fully human monoclonal IgG1 antibody that specifically targets tumor necrosis factor‑α (TNF‑α). By neutralizing TNF‑α, it reduces inflammation across a variety of autoimmune conditions, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn’s disease, ulcerative colitis, and plaque psoriasis. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Subcutaneous … Read more
Introduction Stelara (ustekinumab) is a fully human IgG1κ monoclonal antibody designed to target key cytokines involved in immune-mediated diseases. It selectively binds to the p40 subunit common to interleukin-12 (IL-12) and interleukin-23 (IL-23), blocking their interaction with cell surface receptors. Stelara is approved for several chronic inflammatory conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease, … Read more
